
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
The financial outlook for 10x Genomics Inc appears positive, driven by projected improvements in production efficiency and increasing throughput, particularly with the Media Luna project expected to enhance quarterly results through 2025. The company's innovative product lines, especially the Xenium and Visium HD platforms, are anticipated to generate robust market demand, contributing significantly to revenue growth. Despite a recent reorganization impacting customer engagement in the Americas, the strong adoption of new offerings suggests potential for improved gross margins in the long term.
Bears say
10x Genomics Inc faces a negative outlook primarily due to the heightened competition that could lead to a loss of market share if competitors successfully develop superior offerings. The company is also encountering challenges such as a tight funding environment affecting research budgets, which may hinder its near- and long-term growth potential, evidenced by a year-over-year revenue decline of approximately 1%, missing estimates. Additionally, the launch of the Visium HD product is critical, as any failure or complications in its rollout could lead to further adverse reactions in the stock's performance.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares